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Abstract
Genetic studies of major depressive disorder and its associated endophenotypes are useful for the identification of
candidate genes. In recent years, variations in non-coding RNA genes, such as miRNAs, have been explored as
novel candidates for psychiatric disorders and related endophenotypes. The aim of the present study was to
evaluate the possible association between a functional polymorphism (rs12720208) in the FGF20 gene, which
regulates its modulation by miR-433, and depressive symptoms in young adults. A sample of 270 participants from
Colombia were evaluated with the Hospital Anxiety and Depression Scale - Depression Subscale (HADS-D) and
genotyped for the rs12720208 polymorphism using a TaqMan assay. A lineal regression analysis was used. A
statistically significant association of the functional polymorphism in the FGF20 gene (rs12720208) with depressive
symptoms was found. It was observed that individuals with the G/A genotype had higher scores for the HADS-D
subscale. Our results are the first description in the scientific literature about a significant association between a
functional polymorphism in the FGF20 gene, which regulates its modulation by miR-433, and depressive symptoms.
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Introduction
Major depressive disorder (MDD) leads to major
personal, physical and social consequences, affecting
more than 350 million people worldwide [1]. Although a
large number of studies on depression have been carried
out, leading to a significant progress in understanding
this psychiatric disorder, there is the need for more
studies to find its molecular risk factors and patho-
physiological mechanisms [2]. Genetic studies of MDD
and its associated endophenotypes are useful for the
identification of candidate genes [2]. Depressive symptoms
are interesting endophenotypes for MDD that have been
used in genetic studies [3]. In recent years, variations in
non-coding RNA genes, such as miRNAs, have been
explored as novel candidates for psychiatric disorders and
related endophenotypes [4].
Polymorphisms in genes that are involved in the
dopaminergic systems have been postulated as novel
candidates for MDD, considering the role of dopamine
in neural processed related to motivation and reward
[2]. The FGF20 gene is a member of the FGF (fibroblast
growth factors) family, composed by 22 members, and it
is located on the 8p21.3 chromosome [5]. Fibroblast
growth factors are polypeptides involved in neural
functions and development; FGF20 gene specifically has
been associated with the development and function of
dopaminergic neurons and it is expressed in prefrontal
cortex and cingulate cortex [6]. In the 3′ untranslated
region (UTR) of this gene, it has been shown that a
functional polymorphism (rs12720208) disrupts a binding
site for miR-433, generating an increase in translation of
FGF [7]. A study found that the rs12720208 polymorph-
ism in a sample of young adults was associated with low
scores in verbal episodic memory in A allele carriers [8].
In addition, they found that the rs12720208 polymorph-
ism can alter FGF20 expression and have effects on hippo-
campal morphology [8].
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FGF20 gene has been associated with psychiatric
disorders such as schizophrenia, attention-deficit and
hyperactivity disorder and it has been reported a dysreg-
ulation of the FGF system in depressive disorder [6].
This relationship is explained in part by the hypothesis
of the role of neurogenesis in depression; in this context,
FGF has been linked to favoring neurogenesis and in
humans FGF action has been involved in the stress
response [6]. Furthermore, some reports have shown an
increase in FGF receptor expression with selective
serotonin reuptake inhibitors treatment in depressive
subjects [9]. However, to date no published study have
reported the association between FGF20 gene and de-
pression; although some studies have reported associ-
ation between another FGF system transcripts, such
as FGF2, FGF12 and FGFR2 with major depressive
disorder [9].
The aim of the current study was to evaluate the pos-
sible association between the functional polymorphism




The current study analyzed a sample of 270 young
adults, living in Bogotá, Colombia. Participants were at
least 18 years or older, were unrelated and did not have
personal history of neuropsychiatric disorders, according
to self-report. The subjects had a mean age of 21.3 years
(SD = 3.8) and 75.1% were women. The socioeconomic
status (SES) of the total sample was represented mainly
by low (33.5%) and medium (44.5%) strata, according to
self-report. All participants signed a written informed
consent and the study was approved by the institutional
ethics committee (Universidad Antonio Nariño).
Assessment of depressive symptoms
To assess the presence of depressive symptoms, the
depression sub-scale (HADS-D) of the Hospital Anxiety
and Depression Scale (HADS) was used. This subscale
has 7 Likert-type items related with common cognitive
and emotional symptoms of depression, mainly anhedo-
nia and it has been extensively used in primary care and
clinical research [10]. It has been validated in Spanish
and in a Colombian sample [11].
Genotyping
A salting out method was used for the extraction of
genomic DNA from 400 μl of peripheral blood. DNA
quantification was carried out in a Qubit 2.0 fluorometer
(Thermo Fisher Scientific, MA, USA) using the Qubit
dsDNA BR assay kit (Thermo Fisher Scientific) and then
normalized to 10 ng/μl and stored at 4 °C until used.
Genotyping of the rs12720208 SNP in the FGF20 gene
was made using the TaqMan SNP genotyping assay
(Thermo Fisher Scientific). For the qPCR reaction, it
was used 5 μl of TaqMan genotyping Master Mix
(Thermo Fisher Scientific), 0.5 μl of the pre-design Taq-
Man probe (c__31674955_10, Thermo Fisher Scientific),
20 ng of genomic DNA and ultra-pure water, for a final
volume of 10 μl. The standardized PCR program for
TaqMan assays was performed in a CFX96 Touch
Real-Time PCR system (BioRad, Hercules, CA, USA).
Genotyping results were analyzed with the CFX Manager
Software v.3.0 (BioRad). A random 10 % of the samples
was reanalyzed for genotyping confirmation.
Statistical analysis
To assess the normal distributions of the HADS-D
score, an analysis of skewness and kurtosis was used. In
addition, the psychometric analysis of the HADS-D was
performed, using Cronbach’s alpha for internal
consistency. These statistical analyses were conducted
with the Statistical Package for the Social Sciences (SPSS
v. 18). Allelic and genotype frequencies, Hardy-Weinberg
equilibrium and the analysis of a possible association of
the genotypes with the HADS-D subscale scores were cal-
culated using the SNPStats program [12]. This program
uses a linear regression model, which was adjusted by age
and gender. The results of this linear regression model
were summarized by the mean and the standard errors of
the compared genotypes showing a p value for the differ-
ences [12].
Results
In the current sample, we found a Cronbach’s alpha of
0.65 for HADS-D. The most frequent genotype was the
G/G, followed by the G/A genotype (91% and 9%,
respectively). The A allele was found in 5% and the G
allele was found in 95% of the sample analyzed. We did
not find the A/A genotype. Our sample was in Hardy
Weinberg equilibrium (p = 1).
A statistically significant association of the functional
polymorphism in the FGF20 gene (rs12720208) with
depressive symptoms was found (Fig. 1).The mean of
individuals with the G/G genotype was 4.96 (SE 0.2) and
of individuals with the genotype G/A 6.44 (SE 0.7). It
was observed that individuals with the G/A genotype
had higher scores for the HADS-D subscale (Fig. 1).
Discussion
There is a need for the identification of additional gen-
etic risk factors for MDD [2]. In this context, the genetic
exploration of endophenotypes for MDD and the study
of novel pathways and mechanisms, such as the analysis
of polymorphisms in miRNA binding sites in genes in-
volved in dopaminergic function, might be useful [4].
The members of the FGF family are potential candidates
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for MDD, considering previous studies that have shown
an association between growth factor levels and hippo-
campal volume, taking into account that hippocampal
volume has been negatively correlated with susceptibility
to stress-induced disease [9], such as anxiety disorders,
including posttraumatic stress disorder.
FGF20 gene has been reported as having neurotrophic
properties associated with the survival of dopamin-
ergic neurons [13]. The results of the current study
showed that young subjects with G/A genotype of the
rs12720208 polymorphism have higher depressive
symptoms compared with G/G carriers. This is con-
cordant with previous studies about lower hippocam-
pal volume in depressive patients. In a meta-analytic
study with 434 depressive subjects and 379 controls
(mean ages from 28.4 to 74.3) it was found that de-
pressive patients had lower hippocampal volume com-
pared with controls [14]. Additional studies reported
that smaller hippocampus volumes have been associ-
ated with severity of depressive symptoms, poor re-
sponse to treatment, age at onset of disease and
history of childhood abuse [1]. Importantly, several
studies have described that the hippocampus is largely
susceptible to life adversities and stress, being a mediator
of the relationship between adversities in early-life and
depression [1]. These results could be correlated, in a fu-
ture research neuroimaging study that would be car-
ried out in individuals who showed high scores in the
HADS-D subscale, since previous findings have shown
that A allele carriers had a decrease in hippocampal vol-
ume [8]. Given that the studies with low mean ages in-
cluded in the meta-analyses did not show significant
hippocampal volume differences [14], age needs to be
taken into account in future studies.
Limitations of the study included a convenience
sample design, which includes a higher proportion of
females. In addition, it was not possible to control for
factors that could be confounding, such as stress, life
adversities and other comorbidities. Further studies in
different populations (other ethnicities) and in patients
with major depressive disorder are needed to replicate
this finding.
Conclusion
In conclusion, we found that the functional polymorph-
ism rs12720208 in the FGF20 gene, which regulates its
modulation by miR-433, is associated with depressive
symptoms in young adults. Our results are the first
description in the scientific literature that found this
significant association and can be understood in the
light of the previous reports showing alterations in
FGF system in patients with affective disorders, in-
cluding MDD [1].
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